Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E18.17 EPS (ttm)13.03 Insider Own0.10% Shs Outstand599.00M Perf Week1.27%
Market Cap141.81B Forward P/E14.76 EPS next Y16.04 Insider Trans-6.55% Shs Float592.91M Perf Month7.77%
Income8.07B PEG2.31 EPS next Q3.50 Inst Own79.60% Short Float1.64% Perf Quarter21.98%
Sales23.40B P/S6.06 EPS this Y14.80% Inst Trans-0.40% Short Ratio4.36 Perf Half Y32.71%
Book/sh18.24 P/B12.98 EPS next Y9.24% ROA12.90% Target Price226.18 Perf Year19.85%
Cash/sh34.81 P/C6.80 EPS next 5Y7.88% ROE71.60% 52W Range166.30 - 237.24 Perf YTD21.61%
Dividend6.40 P/FCF24.94 EPS past 5Y13.70% ROI19.80% 52W High-0.21% Beta1.12
Dividend %2.70% Quick Ratio2.60 Sales past 5Y4.90% Gross Margin82.10% 52W Low42.36% ATR3.19
Employees21500 Current Ratio2.90 Sales Q/Q-2.80% Oper. Margin42.80% RSI (14)78.46 Volatility1.21% 1.36%
OptionableYes Debt/Eq2.73 EPS Q/Q14.10% Profit Margin34.50% Rel Volume0.89 Prev Close235.99
ShortableYes LT Debt/Eq2.54 EarningsJan 28 AMC Payout43.30% Avg Volume2.23M Price236.74
Recom2.20 SMA202.69% SMA509.34% SMA20022.30% Volume1,990,783 Change0.32%
Nov-12-19Initiated SunTrust Buy $256
Nov-05-19Upgrade Cantor Fitzgerald Neutral → Overweight $230 → $255
Oct-17-19Resumed BofA/Merrill Neutral $215
Aug-19-19Downgrade Mizuho Buy → Neutral $208 → $212
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Outperform $208
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-13-19 04:07PM  Investors Are Heavily Buying These 19 Stocks Investor's Business Daily
08:10AM  The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer Benzinga
Dec-12-19 09:36AM  Amgen's Osteoporosis Drug Evenity Gets Approval in Europe Zacks
07:38AM  The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win Benzinga
01:00AM  European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture PR Newswire
Dec-11-19 05:45PM  Amgen (AMGN) Gains But Lags Market: What You Should Know Zacks
04:18PM  Amgen board hikes dividend by 10% MarketWatch
04:00PM  Amgen Announces 10% Increase In 2020 First Quarter Dividend PR Newswire
09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
Dec-10-19 10:10AM  Biotech ETFs Hit New Highs on Deal Activities Zacks
09:02AM  Healthpeak Amends & Extends Lease With Amgen in San Francisco Zacks
07:30AM  Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting PR Newswire
Dec-09-19 09:01PM  Stocks Hold Against Resistance Investopedia
04:00PM  Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease PR Newswire
10:03AM  World's largest biotech company to move up to BioMed's big South City project American City Business Journals
09:02AM  Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar Zacks
09:00AM  Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub PR Newswire
Dec-07-19 08:35AM  The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling Benzinga
Dec-06-19 02:31PM  FDA Approves Amgen's AVSOLA (infliximab-axxq), For The Same Indications As Remicade® (infliximab) PR Newswire
12:34PM  UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug Reuters
12:09PM  FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug Reuters
10:22AM  Money Is Moving Back Into Surging Biotech Funds
09:30AM  Biogen Up on New Data on Alzheimer's Candidate Aducanumab Zacks
Dec-05-19 08:00AM  The Biggest Biotech Just Touched A Record High Is Amgen Stock A Buy? Investor's Business Daily
Dec-03-19 06:57PM  Hanging On: Stocks Catch Support Investopedia
02:01PM  Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel Reuters
11:22AM  Cramer Weighs In On Biogen, Caterpillar And More Benzinga
09:29AM  Biogen's Shares Down on Rating Downgrade by Baird Analyst Zacks
09:26AM  Where to Buy Booming Biotech ETFs Investopedia
09:24AM  Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer Zacks
09:24AM  Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead
09:10AM  Abarca, Amgen Enter Outcome-Based Agreement For Enbrel PR Newswire
Dec-02-19 04:00PM  Amgen Announces Data Being Presented At ASH 2019 PR Newswire
11:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
07:00AM  Heart Drugs Are Having a Moment Bloomberg
Nov-29-19 11:24AM  The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx Zacks
08:13AM  Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates Benzinga
Nov-28-19 10:33PM  Were Hedge Funds Right About Warming Up To Amgen, Inc. (AMGN)? Insider Monkey
09:31AM  Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue? Zacks
08:44AM  Here's Why Merck's (MRK) Shares Are Up This Year Zacks
Nov-27-19 10:12AM  Merck's Keytruda Gets Nod in China for Difficult Lung Cancer Zacks
10:09AM  Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More Zacks
Nov-26-19 05:54PM  BeiGene Shares Climb Nearly 50% After Amgen Deal
07:19AM  Novartis Securities Investment Ltd -- Moody's affirms Novartis' A1 rating; stable outlook Moody's
Nov-25-19 10:24AM  Novartis (NVS) to Acquire The Medicines Company for $9.7B Zacks
10:06AM  Biotech Stocks Awaken From Long Slumber Investopedia
09:42AM  The Medicines Company to be Acquired by Novartis for $9.7B Zacks
Nov-23-19 11:02PM  Here is The 14th Most Popular Stock Among 752 Hedge Funds Insider Monkey
03:41PM  Pfizer Is the Dows Worst Stock. A New Strategy Makes It Worth Another Look.
Nov-22-19 09:43AM  The Zacks Analyst Blog Highlights: Facebook, Bank of America, Home Depot, Amgen and Intuitive Zacks
09:43AM  Amgen (AMGN) Completes Otezla Buyout, Raises 2019 Guidance Zacks
09:27AM  Catching Up With Bristol-Myers Stock After Celgene Acquisition
08:28AM  Biotech Stock Funds Just Arent Getting a Break From Outflows
08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
03:32AM  News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon
Nov-21-19 05:58PM  Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal Zacks
04:28PM  Amgen Wraps Otezla Takeover And Other Fallout From BMY's Celgene Buy Investor's Business Daily
03:34PM  Top Stock Reports for Facebook, Bank of America & Home Depot Zacks
02:41PM  Biogen, Novartis named in settlement between foundation, federal prosecutors American City Business Journals
10:00AM  Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer Zacks
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
07:00AM  Market Morning: GM Sues Fiat, Pharma Fights for Pricing Privacy, More Opioid Lawsuits, Trade Deal Troubles Market Exclusive
06:42AM  Amgen raises full-year guidance after closing $13.4 billion Otezla acquisition MarketWatch
06:41AM  Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug Reuters
06:21AM  Amgen Completes Acquisition Of Otezla® (apremilast) PR Newswire
Nov-20-19 04:36PM  Bristol-Myers Squibb completes $74 billion acquisition of Celgene MarketWatch
12:08PM  Yield Curve Inversion: The Complete Picture
Nov-19-19 11:02AM  A $5 Billion Cholesterol Bet May Be an Overreach Bloomberg
10:32AM  Merck's Heart Failure Candidate Meets Goal in Phase III Study Zacks
10:23AM  Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira Zacks
10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
Nov-18-19 09:18AM  Bristol-Myers Gets FTC Clearance for Celgene Acquisition Zacks
09:00AM  New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function PR Newswire
09:00AM  New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function GlobeNewswire
Nov-17-19 03:40PM  AbbVie's Humira on Pace to Become Biggest Seller by 2024
Nov-16-19 09:00AM  Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack PR Newswire
Nov-15-19 05:43PM  FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition MarketWatch
09:10AM  Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion Zacks
09:00AM  Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors PR Newswire
Nov-14-19 09:58AM  Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength Zacks
Nov-12-19 11:37AM  Buy Big Biotech But Not Gilead, Analyst Says
08:26AM  Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Zacks
Nov-11-19 12:51PM  Drugmaker Amgen cuts a quarter of its Kendall Square research staff American City Business Journals
09:00AM  Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio PR Newswire
07:04AM  Amgen at 52-Week Highs Bumps Against Resistance, Remains a Long-Term Hold
Nov-08-19 08:24AM  Biotech Funds Are Beating the Market, but Investors Are Still Bailing Out
Nov-07-19 05:01PM  Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference PR Newswire
Nov-06-19 11:10AM  Radius (RDUS) Q3 Earnings Beat Estimates on Tymlos Strength Zacks
09:33AM  Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down Zacks
Nov-05-19 03:57PM  Top Analyst Reports for Verizon, McDonald's & TOTAL Zacks
11:02AM  Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View Zacks
04:59AM  Novartis gets U.S. nod for long-delayed Amgen copycat Reuters
Nov-04-19 05:05PM  Biotech ETFs in Focus on Impressive Q3 Earnings Results Zacks
01:00PM  Value Biotech ETFs & Stocks to Buy Now Zacks
11:38AM  What's in the Cards for Teva (TEVA) This Earnings Season? Zacks
11:23AM  Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More Zacks
11:20AM  Eaton Vance Worldwide Health Sciences Fund Buys 2 Stocks
01:00AM  Rounding Up Big Pharma Earnings Morningstar
Nov-01-19 03:18PM  Biotech ETFs Strengthen as Amgen Invests in Chinas BeiGene ETF Trends
02:47PM  AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View Zacks
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; Syapse; and DaVita Inc., as well as strategic research partnership with the University of Washington's Institute for Protein Design. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meline David WEVP & CFONov 25Sale234.368,7372,047,60349,378Nov 25 06:27 PM
Graham Jonathan PEVP, Gen. Counsel & Secy.Nov 22Sale230.549,0002,074,83742,853Nov 25 06:25 PM
Piacquad DavidSVP, Business DevelopmentNov 20Option Exercise156.355,749898,85653,361Nov 20 08:09 PM
SUGAR RONALD DDirectorNov 06Option Exercise54.712,000109,42016,436Nov 07 06:20 PM
Williams R SandersDirectorNov 06Sale215.4542591,5665,413Nov 07 06:22 PM
SUGAR RONALD DDirectorNov 06Sale215.452,000430,90014,436Nov 07 06:20 PM
SUGAR RONALD DDirectorOct 02Option Exercise54.712,000109,42016,436Oct 03 05:06 PM
SUGAR RONALD DDirectorOct 02Sale193.582,000387,16014,436Oct 03 05:06 PM
SUGAR RONALD DDirectorSep 04Option Exercise54.712,000109,42016,336Sep 04 06:08 PM
SUGAR RONALD DDirectorSep 04Sale206.702,000413,40014,336Sep 04 06:08 PM
Patton Cynthia MSVP & CCOAug 30Option Exercise158.438,6241,366,33132,648Sep 04 06:07 PM
Patton Cynthia MSVP & CCOAug 30Sale208.0713,4262,793,51022,097Sep 04 06:07 PM
SUGAR RONALD DDirectorAug 07Option Exercise54.712,000109,42016,336Aug 08 07:09 PM
Williams R SandersDirectorAug 07Sale183.0442577,7925,838Aug 08 07:12 PM
SUGAR RONALD DDirectorAug 07Sale183.042,000366,08014,336Aug 08 07:09 PM
SUGAR RONALD DDirectorJul 03Option Exercise54.712,000109,42016,336Jul 08 04:23 PM
SUGAR RONALD DDirectorJul 03Sale187.582,000375,16014,336Jul 08 04:23 PM
SUGAR RONALD DDirectorJun 05Option Exercise54.712,000109,42016,219Jun 05 06:55 PM
SUGAR RONALD DDirectorJun 05Sale175.682,000351,36014,219Jun 05 06:55 PM
SUGAR RONALD DDirectorMay 01Option Exercise54.712,000109,42015,092May 03 05:37 PM
SUGAR RONALD DDirectorMay 01Sale175.732,000351,46013,092May 03 05:37 PM
SUGAR RONALD DDirectorApr 03Option Exercise54.712,000109,42015,092Apr 03 06:27 PM
SUGAR RONALD DDirectorApr 03Sale193.182,000386,36013,092Apr 03 06:27 PM
SUGAR RONALD DDirectorMar 06Option Exercise54.712,000109,42014,988Mar 08 07:47 PM
SUGAR RONALD DDirectorMar 06Sale188.882,000377,76012,988Mar 08 07:47 PM
SUGAR RONALD DDirectorFeb 07Option Exercise54.712,000109,42014,988Feb 11 09:27 PM
SUGAR RONALD DDirectorFeb 07Sale190.002,000380,00012,988Feb 11 09:27 PM